Mukunda Ram

CEO, DirectorIGC Pharma, Inc. (IGC) · full profile →Form 4 · filed Mar 18, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
15
7 non-derivative · 8 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 13, 2024Option exercise(M)251K$03.7M
Mar 13, 2024Option exercise(M)17K$0811K
Mar 13, 2024Option exercise(M)17K$0794K
Mar 13, 2024Gift(G)200K$03.5M
Mar 13, 2024Option exercise(M)333K$03.5M
Mar 13, 2024Option exercise(M)233K$03.1M
Mar 13, 2024Option exercise(M)333K$02.9M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 13, 2024Grant(A)1.5M$00
Mar 13, 2024Option exercise(M)251K$0784K
Mar 13, 2024Option exercise(M)333K$0667K
Mar 13, 2024Option exercise(M)333K$00
Mar 13, 2024Option exercise(M)233K$0233K
Mar 13, 2024Option exercise(M)17K$033K
Mar 13, 2024Grant(A)1.0M$00
Mar 13, 2024Option exercise(M)17K$00

Transaction Codes

M
Option exercise / conversion
G
Gift
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001185185-24-000267) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Ask your agent about IGC insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001185185-24-000267"
Ask your agent
Use Arkolith to summarize insider buying and selling at IGC Pharma, Inc.
over the last 90 days and cite the filings.